Antidepressant-drug interactions are potentially but rarely clinically significant (Q36538987)

14 August 2017

1 reference

title

Antidepressant-drug interactions are potentially but rarely clinically significant (English)

1 reference

14 August 2017

C Lindsay DeVane

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

14 August 2017

published in

Neuropsychopharmacology

1 reference

14 August 2017

volume

31

1 reference

14 August 2017

issue

8

1 reference

14 August 2017

page(s)

1594-604; discussion 1614-5

1 reference

SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Computerized survelliance of adverse drug reactions in hospital: pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Changes in plasma protein binding have little clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Drug interactions in primary care: impact of a new algorithm on risk determination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Present and future in vitro approaches for drug metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Human cytochromes P450: problems and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Relative mortality from overdose of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Database analyses for the prediction of in vivo drug-drug interactions from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Terfenadine-antidepressant interactions: an in vitro inhibition study using human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Drug-drug interactions among elderly patients hospitalized for drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Inhibition of CYP2D6 activity by bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Drug glucuronidation in clinical psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Torsades de pointes occurring in association with terfenadine use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Frequency and cost of serious adverse drug reactions in a department of general medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Inhibition and induction of human cytochrome P450 (CYP) enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Bupropion plasma levels and CYP2D6 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Inhibitors of imipramine metabolism by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

CYP2D6 inhibition in patients treated with sertraline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Drug Metabolism and Drug Interactions: Application and Clinical Value of In Vitro Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Inhibition of P-glycoprotein by newer antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Commentary: a physiological approach to hepatic drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

Sex is a major determinant of CYP3A4 expression in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Elevated antidepressant plasma levels after addition of fluoxetine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Metabolic interaction between fluoxetine and clomipramine: a case report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Prescription-event monitoring of 10,401 patients treated with fluvoxamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Adverse Drug Events in Ambulatory Care

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Pharmacogenetic phenotyping and genotyping. Present status and future potential.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Drug Interaction: Inhibitory Effect of Neuroleptics on Metabolism of Tricyclic Antidepressants in Man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Clinical importance of the interaction of diazepam and cimetidine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Fluoxetine impairs clearance of alprazolam but not of clonazepam

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Importance of protein binding for the interpretation of serum or plasma drug concentrations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Increased carbamazepine plasma concentrations after fluoxetine coadministration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Cigarette smoking and theophyiiine clearance and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Role of cytochrome P450 enzymes in drug-drug interactions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

A fluvoxamine-caffeine interaction study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Sildenafil: clinical toxicology profile

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

The effect of sertraline on the pharmacokinetics of desipramine and imipramine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Drug interaction potential of fluoxetine, sertraline, and paroxetine in four state psychiatric hospital populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Fluvoxamine-clozapine dose-dependent interaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Neuroloeptic effect on desipramine steady-state plasma concentratins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Fluvoxamine-Clozapine Drug Interaction: Inhibition In Vitro of Five Cytochrome P450 Isoforms Involved in Clozapine Metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Inhibition by fluoxetine of cytochrome P450 2D6 activity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Population-Based Studies of Adverse Drug Effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Plasma Protein Displacement Interactions Are Rarely of Clinical Significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

A possible bupropion and imipramine interaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

The clinician and drug interactions--an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Tricyclic antidepressant plasma levels after fluoxetine addition.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

In vitro approaches to predicting drug interactions in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Review of fluvoxamine safety database

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Fluvoxamine. A review of its safety profile in world-wide studies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Sex is a major determinant of CYP3A4 expression in human liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

In vitro metabolic interaction studies: experience of the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301069

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301069

1 reference

release_tp7ldz64zzbq7gwbjiq3wuc3xy

14 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tp7ldz64zzbq7gwbjiq3wuc3xy

24 November 2022

mapped directly with Wikidata item

1 reference